UJohnson & Johnson namuhla bamemezele imiphumela emisha yokuqala yocwaningo lweSisonke lwaseNingizimu Afrika lweSigaba 3b olubonise ukuthi i-booster shot yomuthi wokugomela i-Johnson & Johnson COVID-19 (Ad26.COV2.S) ukhombise ukusebenza kahle okungamaphesenti angama-85 ku-COVID- Ukulaliswa esibhedlela okuhlobene ne-19. Ucwaningo, olwenziwa yiSouth African Medical Research Council (SAMRC), luveze ukuthi i-Johnson & Johnson booster inciphise ubungozi bokulaliswa esibhedlela ngenxa ye-COVID-19 kubasebenzi bezempilo eNingizimu Afrika ngemuva kokuthi u-Omicron ephenduke isidlaliso. Phakathi nezinyanga okufundwa ngazo (maphakathi no-November kuya maphakathi no-December) imvamisa ye-Omicron inyuke isuka kumaphesenti angama-82 yaya kumaphesenti angama-98 abantu abake bathole i-COVID-19 eNingizimu Afrika njengoba kubikwe i-GISAID, isinyathelo esihlinzeka ngedatha ye-COVID-19.
Ukuhlaziywa kwesibili, okuhlukene kokuphendula kwamasosha omzimba emithini yokugoma ehlukene, okwenziwa yiBeth Israel Deaconess Medical Center (BIDMC), kukhombise ukuthi i-heterologous booster (umuthi wokugoma ohlukile) womgomo kaJohnson & Johnson COVID-19 kubantu abaqale bathola i-BNT162b2. Umuthi wokugomela i-mRNA ukhiqize ukwanda okuphindwe ka-41 ekuphenduleni kwe-antibody kanye nokwanda okuphindwe ka-5 kuma-CD8+ T-cell ku-Omicron ngamaviki amane kulandela ukukhushulwa. Ukukhula okulinganayo nge-BNT162b2 kukhiqize ukwanda okuphindwe ka-17 kumasosha omzimba anciphisa amandla kanye nokwanda okuphindwe ka-1.4 kumaseli e-CD8+ T ngamaviki amane kulandela ukukhushulwa. Kokubili amasosha omzimba anciphisa amandla kanye namaseli e-CD8+ T-cell abephezulu emasontweni amane ngemva kokukhushulwa ngomuthi wokugoma u-Johnson & Johnson kunomgomo we-BNT162b2.
Ukwanda kwamaseli e-CD8+ T-cell akhiqizwe umgomo ka-Johnson & Johnson kungase kube ukhiye ekuchazeni amazinga aphezulu okusebenza ngempumelelo ngokumelene nesifo esinzima se-COVID-19 kanye nokulaliswa esibhedlela ocwaningweni lwe-Sisonke 2, njengoba okuhlukile kwe-Omicron kuboniswe ukuthi kubalekela amasosha omzimba abangela amandla.
Idatha ihanjiswe kuseva yokuphrinta ngaphambilini i-medRxiv ngababhali bezifundo, kulindelwe ukushicilelwa kumajenali abuyekezwe ngontanga.
Isigaba 3b Sisonke 2 Ucwaningo Lokulekelela Ezisebenzini Zokunakekelwa Kwezempilo eNingizimu Afrika
Idatha evela ocwaningweni lwe-Sisonke 2 (n=227,310), olwenziwa phakathi kwabasebenzi bezempilo eNingizimu Afrika abathole umgomo we-Johnson & Johnson COVID-19 oyisibhamu esisodwa njengedosi eyinhloko, ikhombisa ukuthi i-Johnson & Johnson COVID-19 booster inyuse ukusebenza komgomo. (VE) ngokumelene nokulaliswa esibhedlela kumaphesenti angama-85. Lapho kuthathwa i-booster shot ezinyangeni eziyisithupha kuya kweziyisishiyagalolunye ngemuva komthamo owodwa oyinhloko, i-VE yenyuke ngokuhamba kwesikhathi isuka kumaphesenti angama-63 (95% CI, 31-81%) ngezinsuku eziyi-0-13, yaya kumaphesenti angama-84 (95% CI, 67-92). %) ngezinsuku eziyi-14-27 kanye namaphesenti angama-85 (95% CI, 54-95%) ezinyangeni ezi-1-2 zokukhulisa.
ISisonke 2 yenziwa ezikhungweni zokugoma ezibalelwa ku-350 kuzo zonke izifundazwe eziyisishiyagalolunye zaseNingizimu Afrika. Besebenzisa idatha evela ku-Discovery Health, inhlangano yokunakekela ephethwe yaseNingizimu Afrika, abaphenyi bocwaningo bathole i-VE ye-Johnson & Johnson COVID-19 booster shot (n=69,092) uma kuqhathaniswa nabanye abantu ababhalise enhlanganweni efanayo yokunakekela ephethwe, phakathi nenkathi kusukela ngoNovemba. 15, 2021, kuze kube nguDisemba 20, 2021.
Ukubhaliswa kwengalo ye-Sisonke 2 yocwaningo kwaqala ngaphambi nje kokuqala kwegagasi le-Omicron eNingizimu Afrika, okuvumela abacwaningi ukuthi bahlole ukusebenza komgomo weNkampani wokugomela i-COVID-19 ikakhulukazi njengoba i-Omicron yaba uhlobo oluvelele ezweni. Ukucaciswa kwe-genomic kokuhlukaniswa namacala e-COVID-19 akuzange kwenziwe kuleli cala.
Abasebenzi bezempilo basengcupheni eyengeziwe yokutheleleka nge-COVID-19, futhi emazweni anjengeNingizimu Afrika, anabantu abaningi abaphila nezifo ezithathelwanayo, imithelela yokutheleleka kwe-SARS-CoV-2 kubasebenzi bezokunakekelwa kwempilo ijulile kakhulu. Iningi labasebenzi bezokunakekelwa kwempilo baseNingizimu Afrika abashone ngenxa ye-COVID-19 okungenani babe ne-commorbidity eyodwa, futhi abaningi babenezifo eziningi zokugula.
I-Antibody kanye Nezimpendulo ze-T-Cell Ngemva Kwe-Heterologous Boosting Regimen Enkulu kune-After Homologous Regimen Against Omicron Variant
Ukuhlaziywa kwabantu abangu-65 abathole ukugoma okuyisisekelo ngemithamo emibili yomgomo we-mRNA COVID-19 (BNT162b2), kulandelwa i-homologous booster shot ye-BNT162b2 (n=24) noma i-booster ye-heterologous enomgomo we-Johnson & Johnson COVID-19 ( n=41) ngemva okungenani kwezinyanga eziyisithupha, kutholwe zombili izinhlobo zemithi zandise izimpendulo ze-humoral kanye namaselula ngokumelene ne-Omicron.
Izimpendulo ze-antibody ezimelene no-Omicron zikhuthazwe yiwo womabili umgomo wokugomela i-Johnson & Johnson COVID-19 kanye nomuthi wokugomela i-BNT162b2, ngomgomo kaJohnson & Johnson COVID-19 okhuphule ama-antibody titers angasebenzi ngokuphindwe ka-41 emasontweni amane ngemva kokuthuthukiswa. Umuthi wokugomela i-BNT162b2 utholwe ukhuphula ama-antibody titers ezingeni eliphakeme ngeviki lesibili lokuthuthukisa, ngaphambi kokuthi wenqabe ukumela ukwanda okuphindwe ka-17 ngeviki le-post-boost ezine. Ukwanda okuqhubekayo kwamasosha omzimba emasontweni alandela ukugonywa kwe-booster ka-Johnson & Johnson kufana nalokho okubonwa ngemva komgomo wokuqala. Ukusabela okusheshayo kokuzivikela komzimba okulandelwa ukuncipha kokusabela kwe-antibody ngemva kwe-booster ye-BNT162b2 nakho kuyafana nalokho okubonwa ngemva kohlobo lokuqala lwemithamo emibili.
Umuthi wokugomela i-Johnson & Johnson COVID-19 ukhulise ama-CD8+ T-cell amaphakathi ngo-5.5-fold, nama-Omicron-reactive CD4+ T-cells ngo-3.1-fold, kuyilapho uhlobo lwe-homologous (BNT162b2) lukhulise kokubili i-Omicron-reactive CD4+ ne-CD8+ T-cells ngo-1.4-fold.
Ama-T-cell angakhomba futhi abhubhise amaseli angenwe yileli gciwane elibangela i-COVID-19 futhi kukholakala ukuthi aneqhaza ekuvikelekeni ezifweni ezinzima. Ngokuqondile, ama-CD8+ T-cell angabhubhisa amaseli angenwe yileli gciwane futhi asizwa ama-CD4+ T-cell.
Le datha iphakamisa ukuthi ukukhuliswa kwe-heterologous kunamandla okwenza ukuzivikela okuqinile kwe-cell-mediated, okubalulekile kwinkumbulo yokuzivikela komzimba nokuvikela ezifweni ezinzima zepheshana lokuphefumula eliphansi. Ukuqina kwemithi yokuqinisa i-heterologous kanye ne-homologous yokuhluka kwe-SARS-CoV-2 Omicron kusazonqunywa.
Ulwazi Olwengeziwe
Umuthi wokugomela i-Johnson & Johnson COVID-19 ugunyazwe njenge-booster ngabaqondisi abaningi nezinhlangano zokunakekelwa kwezempilo emhlabeni jikelele. U-Johnson & Johnson uyaqhubeka nokuthumela idatha efanele kwabanye abalawuli, i-World Health Organization (WHO) kanye nama-National Immunisation Technical Advisory Groups (NITAGs) emhlabeni wonke ukuze bazise ukuthathwa kwezinqumo ngamasu okuphatha umgomo wendawo, njengoba kudingeka.
Mhla ziyi-16 kuZibandlela wezi-2021, i-US Centers for Disease Control and Prevention (CDC) yagunyaza izincomo ezibuyekeziwe ezenziwe yiKomidi Lokweluleka Lemikhuba Yokugoma (ACIP) zokuvimbela i-COVID-19, izwakalisa ukukhetha komtholampilo kokuthi abantu bathole i-mRNA COVID. -19 umuthi wokugomela i-Johnson & Johnsons COVID-19. E-US, abantu abangakwazi noma abangazimisele ukuthola umgomo we-mRNA bazoqhubeka nokufinyelela kumgomo wokugomela i-Johnson & Johnson COVID-19.
Umuthi wokugoma i-Johnson & Johnson COVID-19 uyinketho ebalulekile yabantu abangakwazi noma abangeke babuye ukuze bayothola imigomo eminingi noma abazohlala bengagonyiwe ngaphandle kwenye indlela yokugomela i-mRNA. Umuthi wokugomela i-Johnson & Johnson COVID-19 uhambisana nezincomo ze-World Health Organization (WHO) zokungenelela kwezokwelapha esimweni esiwubhubhane, ogcizelela kalula ukusatshalaliswa, ukuphatha, nokuhambisana.